← Back to Search

Survivorship Care Coordination for Prostate Cancer

Mount Vernon, IL
N/A
Waitlist Available
Led By Ronald C Chen
Research Sponsored by NRG Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The ADT must be planned for at least 4 months and must include luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist
The participant must be able to complete required questionnaires in English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline and 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether increasing the coordination of care between the cancer care team and the primary care team improves care and outcomes for prostate cancer survivors.

See full description
Who is the study for?
This trial is for prostate cancer survivors who are undergoing radiation and androgen deprivation therapy. They must be able to fill out questionnaires in English, have a primary care provider or cardiologist, and consent to the study. Practices need IRB approval, complete specific training, and follow certain protocols. Patients already on ADT for no more than 120 days may join.Check my eligibility
What is being tested?
The trial tests if increasing survivorship care planning can improve outcomes for prostate cancer survivors on therapy that raises risks of diabetes and heart issues. It compares standard care with an increased dose of coordinated survivorship care between oncologists and primary caregivers.See study design
What are the potential side effects?
Since this trial focuses on survivorship care planning rather than a medical intervention, there are no direct side effects from treatments like drugs or surgery being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for hormone therapy for my cancer for at least 4 months.
 show original
Select...
I can complete questionnaires in English.
 show original
Select...
I have prostate cancer and will be treated with radiation and hormone therapy aiming for a cure.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline and 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of patients who saw a primary care provider (PCP) or cardiologist and had fasting blood glucose and cholesterol checked
Secondary study objectives
Calculated cardiovascular (CVD) risk score
Coordination of care with respect to the PCP or cardiologist
Current practice related to SCP delivery and prostate cancer survivor monitoring
+3 more
Other study objectives
Coordination of care with respect to the cancer specialist
Satisfaction of care with respect to the cancer specialist

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm B (enhanced SCP)Experimental Treatment3 Interventions
Practices review a treatment plan with patient and send it to the PCP at the beginning of RT. Practices also review a SCP as arm A.
Group II: Arm A (standard)Active Control2 Interventions
Practices review a SCP with patients and send it to the PCP during the last week of RT.

Find a Location

Closest Location:SSM Health Good Samaritan· Mount Vernon, IL

Who is running the clinical trial?

NRG OncologyLead Sponsor
241 Previous Clinical Trials
104,441 Total Patients Enrolled
National Cancer Institute (NCI)NIH
14,057 Previous Clinical Trials
41,148,882 Total Patients Enrolled
Ronald C ChenPrincipal InvestigatorNRG Oncology
1 Previous Clinical Trials
586 Total Patients Enrolled

Media Library

Survivorship Care Planning Clinical Trial Eligibility Overview. Trial Name: NCT03860961 — N/A
Prostate Adenocarcinoma Research Study Groups: Arm A (standard), Arm B (enhanced SCP)
Prostate Adenocarcinoma Clinical Trial 2023: Survivorship Care Planning Highlights & Side Effects. Trial Name: NCT03860961 — N/A
Survivorship Care Planning 2023 Treatment Timeline for Medical Study. Trial Name: NCT03860961 — N/A
~83 spots leftby Mar 2026